Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet + Taxotere first-line safety study in advanced breast cancer
2005-002004-42Phase 2Active
- Sponsor
- Grupo Oncopaz
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and docetaxel in breast cancer, sponsored by Grupo Oncopaz. Primary endpoint: Objective cardiotoxicity rate. Started Sep 2005; status: active.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-002004-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002004-42.